Condition (MeSH)
Iron Metabolism Disorders
ClinicalTrials.gov lists 1,040 trials for Iron Metabolism Disorders or a narrower condition beneath it. Novartis Pharmaceuticals has the most among industry and government lead sponsors, with 32.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
1 more section with rows
19 of the 1,040 trials are tagged with Iron Metabolism Disorders itself; the rest are tagged with a narrower condition beneath it.
When did Iron Metabolism Disorders trials start? (34)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
- Other (Expanded access)
Top of scale: 65
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 48 |
| 2025 | 56 |
| 2024 | 54 |
| 2023 | 54 |
| 2022 | 62 |
| 2021 | 65 |
| 2020 | 43 |
| 2019 | 63 |
| 2018 | 53 |
| 2017 | 58 |
Showing 10 of 34 earlier years.
Forecast of the full-year count, planned starts included, not rows of this table: about 60 trials starting in 2026 and about 53 in 2027, the average of the 24 months through September, counted as registered and carried forward, with about 0.7 times the starts already registered for the rest of 2026 added. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 15 percent and ran about 1 percent high against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. The part-way figures are from forecasts that used a multiple fitted only on earlier years. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.
Prediction, not a registry value: median of 36 months from start to primary completion across 75 trials still running at the 2026-10-09 snapshot; registered median of 17 months across 696 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Iron Metabolism Disorders trials in? (9)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 43 |
| Phase 1/2 | 9 |
| Phase 2 | 79 |
| Phase 2/3 | 16 |
| Phase 3 | 120 |
| Phase 4 | 160 |
| Not applicable | 363 |
| Observational | 249 |
| Expanded access | 1 |
How many Iron Metabolism Disorders trials are recruiting? (10)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 40 |
| Recruiting | 99 |
| Enrolling by invitation | 2 |
| Active, not recruiting | 13 |
| Completed | 648 |
Showing 5 of 10 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Iron Metabolism Disorders trials? (6)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Novartis Pharmaceuticals | 32 |
| Pharmacosmos A/S | 16 |
| American Regent, Inc. | 13 |
| Vifor Pharma | 13 |
| AMAG Pharmaceuticals, Inc. | 11 |
Showing 5 of 6 sponsors.
Which drugs are being tested for Iron Metabolism Disorders? (5)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Fer-In-Sol | 98 |
| Iron | 27 |
| Ferric Derisomaltose | 14 |
| Ferric Maltol | 14 |
| Talactoferrin | 9 |
Interventions as named in the registry (10)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Ferricarboxymaltose | 67 |
| Deferasirox FCT | 40 |
| i.v. iron sucrose | 37 |
| 10% Iron Isomaltoside 1000 | 22 |
| FERINJECT® (Ferric carboxymaltose) | 19 |
Showing 5 of 10 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Iron Metabolism Disorders trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Adverse side effects (GI distress, constipation, vomiting, diarrhea) | 428 | 1 |
| Cardiac failure | 273 | 13 |
| Pneumonia | 243 | 31 |
| Cardiac failure congestive | 179 | 19 |
| Sickle cell anaemia with crisis | 169 | 6 |
Showing 5 of 10 adverse events.
Which publications cover Iron Metabolism Disorders? (30)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| C19orf12 mutation causing mitochondrial membrane-protein Associated Neurodegeneration masquerading as spastic paraplegia. | Parkinsonism & related disorders | 2021 | Yes |
| Iron deficiency during first-line chemotherapy in metastatic cancers: a prospective epidemiological study. | Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer | 2020 | Yes |
| Unexplained isolated hyperferritinemia without iron overload. | American journal of hematology | 2017 | Yes |
| Efficacy and safety of deferasirox in non-thalassemic patients with elevated ferritin levels after allogeneic hematopoietic stem cell transplantation. | Bone marrow transplantation | 2016 | Yes |
| Non-invasive detection of iron deficiency by fluorescence measurement of erythrocyte zinc protoporphyrin in the lip. | Nature communications | 2016 | Yes |
Showing 5 of 30 publications.
Sub-conditions in MeSH (3)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.